Please login to the form below

Not currently logged in
Email:
Password:

Ironwood

This page shows the latest Ironwood news and features for those working in and with pharma, biotech and healthcare.

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug. Duzallo will be launched in the US before the end of this year. ... alone - perhaps modest for AZ but significant for Ironwood which made $274m in total revenues last year.

Latest news

  • FDA approves Synergy's constipation drug Trulance FDA approves Synergy's constipation drug Trulance

    Plecanatide's closest competitor in the market is Ironwood/Allergan's Linzess/Constella (linaclotide), described as a guanylate cyclase stimulant, which is approved for the treatment of constipation-predominant IBS in

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    AZ previously sold US rights to Zurampic and the follow-up to Ironwood Pharmaceuticals for $265m plus royalties. ... The drug is approved for use alongside xanthine oxidase (XO) inhibitors such as generic allopurinol or Takeda's Uloric (febuxostat) in

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    AZ adds gout drug Zurampic to asset sale. Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product. ... Under the terms of the agreement, Ironwood will have certain rights to potentially access RDEA3170 in gout indications

  • AZ and Ironwood to file IBS drug linaclotide in China next year AZ and Ironwood to file IBS drug linaclotide in China next year

    AstraZeneca (AZ) and Ironwood Pharmaceuticals say they are on course to submit irritable bowel syndrome treatment linaclotide for approval in China in early 2016. ... Linaclotide is a guanylate cyclase‐ C agonist that is already sold in the US as

  • Pharma social media update - Twitter Pharma social media update - Twitter

    These accounts are joined in the Digital Handbook by ones from GlaxoSmithKline, Gilead Sciences and Ironwood Pharma, plus European pharma association EFPIA and its Italian counterpart the Agenzia Italiana del Farmaco. •

More from news
Approximately 5 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    In a "mirror deal" in April this year, AstraZenenca licensed US rights to Zurampic and the fixed dose combination to Ironwood Pharmaceuticals for $100m upfront and up to $165m in further

  • Deal Watch April 2016 Deal Watch April 2016

    Ironwood is paying $100m upfront for the US market plus $165m of milestones and “ tiered single digit royalties”. ... 450. AstraZeneca (UK). Ironwood (US). US license and commercialisation. Lesinurad (approved) combo in development for treatment of

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In addition, Ironwood could receive a further $125m in milestones if certain sales targets for linaclotide are met. ... 153. Ironwood / AstraZeneca. Co-develop &co-commercialise (profit/ loss share). Linaclotide, IBS with constipation (FDA approved).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel.

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Vertex poaches new finance chief from Ironwood Pharmaceuticals. Boston-based biotech company appoints Tom Graney. ... Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer.

  • Ironwood Pharmaceuticals appoints chief development officer Ironwood Pharmaceuticals appoints chief development officer

    Ironwood Pharmaceuticals appoints chief development officer. Dr Christopher Wright joins from Axcella Health. ... Ironwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development

  • Proteostasis Therapeutics strengthens leadership team Proteostasis Therapeutics strengthens leadership team

    James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Ironwood appoints Edward Owens to board. He brings experience as portfolio manager of Vanguard Health Care Fund. ... Ironwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors.

More from appointments
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics